RNA	0	3	O
damage	4	10	O
and	11	14	O
inhibition	15	25	O
of	26	28	O
neoplastic	29	39	O
endothelial	40	51	B-Cell
cell	52	56	I-Cell
growth	57	63	O
:	63	64	O
effects	65	72	O
of	73	75	O
human	76	81	B-Organism
and	82	85	O
amphibian	86	95	O
ribonucleases	96	109	B-Gene_or_gene_product
.	109	110	O

Angiogenesis	112	124	O
defines	125	132	O
the	133	136	O
many	137	141	O
steps	142	147	O
involved	148	156	O
in	157	159	O
the	160	163	O
growth	164	170	O
and	171	174	O
migration	175	184	O
of	185	187	O
endothelial	188	199	B-Cell
cell	200	204	I-Cell
-	204	205	O
derived	205	212	O
blood	213	218	B-Multi-tissue_structure
vessels	219	226	I-Multi-tissue_structure
.	226	227	O

This	228	232	O
process	233	240	O
is	241	243	O
necessary	244	253	O
for	254	257	O
the	258	261	O
growth	262	268	O
and	269	272	O
metastasis	273	283	O
of	284	286	O
tumors	287	293	B-Pathological_formation
,	293	294	O
and	295	298	O
considerable	299	311	O
effort	312	318	O
is	319	321	O
being	322	327	O
expended	328	336	O
to	337	339	O
find	340	344	O
inhibitors	345	355	O
of	356	358	O
tumor	359	364	B-Pathological_formation
angiogenesis	365	377	O
.	377	378	O

This	379	383	O
usually	384	391	O
involves	392	400	O
screening	401	410	O
of	411	413	O
potential	414	423	O
anti	424	428	O
-	428	429	O
angiogenic	429	439	O
compounds	440	449	O
on	450	452	O
endothelial	453	464	B-Cell
cells	465	470	I-Cell
.	470	471	O

To	472	474	O
this	475	479	O
end	480	483	O
,	483	484	O
two	485	488	O
candidate	489	498	O
anti	499	503	O
-	503	504	O
angiogenic	504	514	O
RNA	515	518	O
-	518	519	O
damaging	519	527	O
agents	528	534	O
,	534	535	O
onconase	536	544	B-Drug_or_compound
and	545	548	O
(	549	550	B-Drug_or_compound
-	550	551	I-Drug_or_compound
4	551	552	I-Drug_or_compound
)	552	553	I-Drug_or_compound
rhEDN	553	558	I-Drug_or_compound
,	558	559	O
were	560	564	O
screened	565	573	O
for	574	577	O
their	578	583	O
effects	584	591	O
on	592	594	O
endothelial	595	606	B-Cell
cell	607	611	I-Cell
proliferation	612	625	O
using	626	631	O
three	632	637	O
distinct	638	646	O
types	647	652	O
of	653	655	O
endothelial	656	667	B-Cell
cells	668	673	I-Cell
in	674	676	O
culture	677	684	O
:	684	685	O
HPV	686	689	B-Organism
-	689	690	I-Organism
16	690	692	I-Organism
E6	693	695	I-Organism
/	695	696	O
E7	696	698	B-Organism
-	698	699	O
immortalized	699	711	O
human	712	717	B-Cell
umbilical	718	727	I-Cell
vein	728	732	I-Cell
endothelial	733	744	I-Cell
cells	745	750	I-Cell
(	751	752	O
HUVECs	752	758	B-Cell
)	758	759	O
,	759	760	O
a	761	762	O
Kras	763	767	B-Gene_or_gene_product
-	767	768	O
transformed	768	779	O
HPV	780	783	B-Organism
-	783	784	I-Organism
16	784	786	I-Organism
E6	787	789	I-Organism
/	789	790	O
E7	790	792	B-Organism
HUVEC	793	798	B-Cell
(	799	800	O
Rhim	800	804	O
et	805	807	O
al	808	810	O
.	810	811	O
,	811	812	O
Carcinogenesis	813	827	O
4	828	829	O
,	829	830	O
673	831	834	O
-	834	835	O
681	835	838	O
,	838	839	O
1998	840	844	O
)	844	845	O
,	845	846	O
and	847	850	O
primary	851	858	O
HUVECs	859	865	B-Cell
.	865	866	O

Onconase	867	875	B-Drug_or_compound
similarly	876	885	O
inhibited	886	895	O
proliferation	896	909	O
in	910	912	O
all	913	916	O
three	917	922	O
cell	923	927	B-Cell
lines	928	933	I-Cell
(	934	935	O
IC	935	937	O
(	937	938	O
50	938	940	O
)	940	941	O
=	942	943	O
0	944	945	O
.	945	946	O
3	946	947	O
-	947	948	O
1	948	949	O
.	949	950	O
0	950	951	O
microM	952	958	O
)	958	959	O
while	960	965	O
(	966	967	B-Drug_or_compound
-	967	968	I-Drug_or_compound
4	968	969	I-Drug_or_compound
)	969	970	I-Drug_or_compound
rhEDN	970	975	I-Drug_or_compound
was	976	979	O
more	980	984	O
effective	985	994	O
on	995	997	O
immortalized	998	1010	O
HUVEC	1011	1016	B-Cell
cell	1017	1021	I-Cell
lines	1022	1027	I-Cell
(	1028	1029	O
IC	1029	1031	O
(	1031	1032	O
50	1032	1034	O
)	1034	1035	O
=	1036	1037	O
0	1038	1039	O
.	1039	1040	O
02	1040	1042	O
-	1042	1043	O
0	1043	1044	O
.	1044	1045	O
06	1045	1047	O
microM	1048	1054	O
)	1054	1055	O
than	1056	1060	O
on	1061	1063	O
primary	1064	1071	O
HUVECs	1072	1078	B-Cell
(	1079	1080	O
IC	1080	1082	O
(	1082	1083	O
50	1083	1085	O
)	1085	1086	O
>	1087	1088	O
0	1089	1090	O
.	1090	1091	O
1	1091	1092	O
microM	1093	1099	O
)	1099	1100	O
.	1100	1101	O

Differential	1102	1114	O
sensitivity	1115	1126	O
to	1127	1129	O
these	1130	1135	O
agents	1136	1142	O
implies	1143	1150	O
that	1151	1155	O
more	1156	1160	O
than	1161	1165	O
one	1166	1169	O
endothelial	1170	1181	B-Cell
cell	1182	1186	I-Cell
type	1187	1191	I-Cell
must	1192	1196	O
be	1197	1199	O
used	1200	1204	O
in	1205	1207	O
proliferation	1208	1221	O
assays	1222	1228	O
to	1229	1231	O
screen	1232	1238	O
for	1239	1242	O
novel	1243	1248	O
anti	1249	1253	O
-	1253	1254	O
angiogenic	1254	1264	O
compounds	1265	1274	O
.	1274	1275	O

